WallStSmart

Insmed Inc (INSM)vsVistaGen Therapeutics Inc (VTGN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 76760% more annual revenue ($606.42M vs $789,000). VTGN leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

VTGN

Avoid

34

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

VTGN2 strengths · Avg: 9.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
29.5%8/10

Revenue surging 29.5% year-over-year

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

VTGN4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$24.42M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-101.6%2/10

ROE of -101.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : VTGN

The strongest argument for VTGN centers on Price/Book, Revenue Growth. Revenue growth of 29.5% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : VTGN

The primary concerns for VTGN are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while VTGN is a growth play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

VTGN is growing revenue faster at 29.5% — sustainability is the question.

VTGN generates stronger free cash flow (-18M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

VistaGen Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential to treat anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.

Want to dig deeper into these stocks?